Legal & General Group Plc Lowers Position in Envista Holdings Corporation $NVST

Legal & General Group Plc cut its stake in Envista Holdings Corporation (NYSE:NVST) by 19.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 250,956 shares of the company’s stock after selling 61,956 shares during the period. Legal & General Group Plc’s holdings in Envista were worth $5,448,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Tudor Investment Corp ET AL purchased a new stake in Envista in the third quarter worth about $1,664,000. First Eagle Investment Management LLC purchased a new stake in Envista in the third quarter worth about $4,329,000. Massachusetts Financial Services Co. MA lifted its holdings in Envista by 15.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,349,874 shares of the company’s stock worth $72,726,000 after buying an additional 444,725 shares during the period. Jupiter Asset Management Ltd. lifted its holdings in Envista by 24.6% in the third quarter. Jupiter Asset Management Ltd. now owns 1,349,042 shares of the company’s stock worth $27,480,000 after buying an additional 266,671 shares during the period. Finally, Fox Run Management L.L.C. purchased a new stake in Envista in the third quarter worth about $880,000.

Analyst Ratings Changes

Several brokerages have commented on NVST. Evercore restated an “outperform” rating and issued a $33.00 price objective on shares of Envista in a report on Thursday, May 7th. JPMorgan Chase & Co. lifted their target price on shares of Envista from $26.00 to $29.00 and gave the company a “neutral” rating in a report on Thursday, May 7th. Robert W. Baird lifted their target price on shares of Envista from $30.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Zacks Research lowered shares of Envista from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Finally, Morgan Stanley lifted their target price on shares of Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Friday, April 24th. Six research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Envista has an average rating of “Hold” and an average price target of $28.83.

Envista Price Performance

NVST stock opened at $23.08 on Monday. The firm has a market capitalization of $3.76 billion, a price-to-earnings ratio of 56.29, a PEG ratio of 1.31 and a beta of 0.88. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.06 and a current ratio of 2.44. The firm has a 50 day moving average price of $25.13 and a 200-day moving average price of $24.58. Envista Holdings Corporation has a 52-week low of $18.25 and a 52-week high of $30.42.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.05. The business had revenue of $705.50 million for the quarter, compared to analysts’ expectations of $680.04 million. Envista had a return on equity of 7.11% and a net margin of 2.41%.The firm’s quarterly revenue was up 14.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Equities research analysts forecast that Envista Holdings Corporation will post 1.42 EPS for the current fiscal year.

Envista Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.